<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117770">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02045069</url>
  </required_header>
  <id_info>
    <org_study_id>ESIDEN</org_study_id>
    <nct_id>NCT02045069</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ivermectin Against Dengue Infection</brief_title>
  <official_title>A Phase II/III, Randomized, Placebo Controlled Trial of Efficacy and Safety of Ivermectin in Children and Adult Patients With Dengue Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <authority>Thailand: Ministry of Public Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a  Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and
      Safety of Ivermectin in Children and Adult patients with Dengue Infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with confirmed dengue infection who meet all inclusion and exclusion criteria will
      be enrolled in the study and admitted in the hospital. Patients will be randomly assigned in
      a pre-specified ratio of 1:1:1 to one of the following study groups: ivermectin 200-400
      µg/kg single daily dose for 2 days, ivermectin 200-400 µg/kg single daily dose for 3 days,
      or placebo. Tablets of ivermectin or placebo will be administered for 3 days. Clinical exam
      will be performed daily during hospitalization and blood samples will be collected for
      hematology, clinical chemistry, serology, viral load and quantitative nonstructural 1 (NS1)
      antigen. Safety assessment will be conducted during admission. Patients will be discharged
      one day after fever subsidence and will be asked to return 2 weeks after first dose of study
      medication for safety assessment and blood sampling.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to resolution of viremia</measure>
    <time_frame>Every 12 hr, from date of randomization until resolution of viremia or until fever subsides for 1 day, whichever came first.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to clearance of NS1 antigen</measure>
    <time_frame>Every 12 hr, from date of randomization until resolution of viremia or until fever subsides for 1 day, whichever came first.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of subsidence of fever</measure>
    <time_frame>From date of randomization until  fever subsides</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Dengue Fever</condition>
  <arm_group>
    <arm_group_label>2 days Ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin 200 - 400 µg/kg once daily for 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 days Ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin 200-400 µg/kg once daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 days Ivermectin</intervention_name>
    <description>200-400 µg/kg once daily for 2 days and placebo once daily at D3</description>
    <arm_group_label>2 days Ivermectin</arm_group_label>
    <other_name>Mectizan</other_name>
    <other_name>Ivomec</other_name>
    <other_name>Stromectol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 days Ivermectin</intervention_name>
    <description>200 -400 µg/kg once daily for 3 days</description>
    <arm_group_label>3 days Ivermectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily for 3 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ages of 15 or greater.

          -  History or presence of fever (temperature &gt; 38°C) of ≤ 72 hr duration.

          -  Clinical suspicion of dengue infection such as high fever without an evidence or
             suspected focus of infection on clinical examination.

          -  Positive NS 1 strip assay

        Exclusion Criteria:

          -  Clinically significant abnormal laboratory results which are deemed to be
             unassociated with dengue infection

          -  Clinical evidence or a history of significant respiratory, metabolic, renal, hepatic,
             hematologic or chronic diseases

          -  History of autoimmune, immune dysfunction disorder or taking warfarin

          -  Clinical suspicion of any bacterial infection

          -  Pregnancy and lactating women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yupin Supputamonkol, MD.</last_name>
    <phone>6681-754-5573</phone>
    <email>ysuputtamongkol@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Panisadee Avirutnan, MD, PhD.</last_name>
    <phone>6681-895-0019</phone>
    <email>panisadee.avi@mahidol.ac.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nasikarn Angkasekwinai, MD</last_name>
      <phone>66818708766</phone>
      <email>nasikarn@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 22, 2014</lastchanged_date>
  <firstreceived_date>January 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Dengue Hemorrhagic Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
